Biotie won't buy Neurelis but epilepsy trial will go ahead
This article was originally published in Scrip
Executive Summary
Biotie Therapies will not be exercising its exclusive option to acquire Neurelis, a private specialty pharmaceutical company. The decision follows the return to Biotie of rights to Parkinson's disease candidate tozadenant in March 2014 from UCB.